title: Acceptability and feasibility of phone follow-up with a semiquantitative urine pregnancy test after medical abortion in Moldova and Uzbekistan.
abstract: OBJECTIVE
  To evaluate the feasibility and acceptability of phone follow-up with a home semiquantitative pregnancy test and standardized checklist, and compare the alternative method of follow-up with in-clinic follow-up after medical abortion.
  
  
  METHODS
  Two thousand four hundred women undergoing medical abortion with mifepristone and misoprostol in Moldova and Uzbekistan were randomized to phone or clinic follow-up. All women in the clinic group returned to the clinic 2 weeks later. Women randomized to phone follow-up used a semiquantitative pregnancy test at the initial visit and repeated the test at home 2 weeks later when they also filled out a symptom checklist. Women were called at 2 weeks to review the test results and checklist. Participants who screened "positive" were referred to clinic to verify abortion completion.
  
  
  RESULTS
  Most women in the phone group were successfully contacted on the phone (97.6%). Staff were unable to contact one woman in the phone follow-up group, and all women in clinic group returned to the clinic. The ongoing pregnancy rate was similar in both groups (0.4-0.6%), and the semiquantitative pregnancy test identified all ongoing pregnancies in the phone follow-up group. Women in the phone group found the test and checklist easy to use, and most (76.1%) preferred phone follow-up in the future. Overall, 92.8% of women in the phone group did not undergo in-clinic follow-up.
  
  
  CONCLUSIONS
  Phone follow-up with a semiquantitative urine pregnancy test and symptom checklist is a feasible and a highly effective approach in identifying ongoing pregnancy after medical abortion.
  
  
  CONCLUSIONS
  The semiquantitative pregnancy test can make home follow-up after medical abortion possible for many women and provide reassurance that ongoing pregnancies will be detected.
authors.affiliation: Gynuity Health Projects, New York, NY 10010, USA. Electronic address: iplatais@gynuity.org.
authors.forename: Ingrida
authors.initials: I
authors.lastname: Platais
authors.affiliation: Gynuity Health Projects, Tbilisi, Georgia.
authors.forename: Tamar
authors.initials: T
authors.lastname: Tsereteli
authors.affiliation: Moldova State Medical University, Reproductive Health Training Center, Chisinau, Moldova.
authors.forename: Rodica
authors.initials: R
authors.lastname: Comendant
authors.affiliation: Women's Wellness Center, Tashkent, Uzbekistan.
authors.forename: Dilfuza
authors.initials: D
authors.lastname: Kurbanbekova
authors.affiliation: Gynuity Health Projects, New York, NY 10010, USA.
authors.forename: Beverly
authors.initials: B
authors.lastname: Winikoff
mesh_terms: D000027:Abortion, Incomplete / Q000175:diagnosis* / Q000453:epidemiology / Q000652:urine; D000028:Abortion, Induced / Q000009:adverse effects*; D000554:Ambulatory Care Facilities; D057189:Checklist; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008966:Moldova / Q000453:epidemiology; D010044:Outpatient Clinics, Hospital; D057240:Patient Preference; D017060:Patient Satisfaction; D011182:Postoperative Care; D011247:Pregnancy; D011258:Pregnancy Tests; D011261:Pregnancy Trimester, First; D011369:Professional-Patient Relations; D012306:Risk; D012648:Self Care; D013689:Telephone; D014610:Uzbekistan / Q000453:epidemiology; D000078329:Workforce
keywords: Checklist; Human chorionic gonadotropin; Mifepristone; Misoprostol; Symptoms